乳腺癌不同转移部位的影响因素分析
|
摘要
目的:分析乳腺癌患者术后不同转移部位间生物学特征的差异,从而筛选可能对转移部位有影响的相关因素。方法:将我院2002年1月～2007年12月间收治并有完整病例资料的121例乳腺癌术后转移患者按照不同转移部位分为骨转移组及脏器转移组(肺转移、肝转移、脑转移),分别采用单因素及多因素分析的方法对两组患者的临床及病理特征进行比较。结果:单因素分析结果显示:原发肿瘤大小、腋窝淋巴结转移状况、雌、孕激素受体及C-erbB-2基因的表达在两组间的差异有统计学意义(P<0.05),提示:上述四种因素可能对乳腺癌术后不同转移部位有影响。进一步运用Logistic回归模型行多因素分析结果显示:C-erbB-2基因的表达在骨转移组及脏器转移组之间的差异有统计学意义( P=0.001)。结论:乳腺癌术后骨转移患者和脏器转移患者的临床及生物学特征存在一定的差异,C-erbB-2基因可能是乳腺癌术后转移部位的影响因素之一。
Objective: To analyze the difference between different metastasis sites of breast cancer patients , and to have knowledge of the regular pattern of metastatic breast cancer . Methods: In January, 2002 ~ in December, 2007 admits to my hospital and has made follow-up visit the material 121 cases with different metastasis sites of breast cancer . We retrospectively analyzed the clinical and the pathology characteristic between the patients with organ metastases(lung,liver,brain) and bone metastases with the single factor and the multi-factor analysis method. Results: The single factor analysis result showed the tumor size, axillary lymph nodes status,ER,PR status and expression of C-erbB-2,have a statistical difference between the two groups(P<0.05). Logistic regression analysis result indicated only the expression of C-erbB-2 affects the metastasis sites of breast cancer patients( P=0.001) Conclusion: There maybe a regular between different part of metastasis breast cancer patients with different clinical and biological characteristics. The expression of C-erbB-2 maybe the factor that influent the metastasis sites of breast cancer patients.
Objective: To analyze the difference between different metastasis sites of breast cancer patients , and to have knowledge of the regular pattern of metastatic breast cancer . Methods: In January, 2002 ~ in December, 2007 admits to my hospital and has made follow-up visit the material 121 cases with different metastasis sites of breast cancer . We retrospectively analyzed the clinical and the pathology characteristic between the patients with organ metastases(lung,liver,brain) and bone metastases with the single factor and the multi-factor analysis method. Results: The single factor analysis result showed the tumor size, axillary lymph nodes status,ER,PR status and expression of C-erbB-2,have a statistical difference between the two groups(P<0.05). Logistic regression analysis result indicated only the expression of C-erbB-2 affects the metastasis sites of breast cancer patients( P=0.001) Conclusion: There maybe a regular between different part of metastasis breast cancer patients with different clinical and biological characteristics. The expression of C-erbB-2 maybe the factor that influent the metastasis sites of breast cancer patients.
引文
[1] Winer EP,Morrow M,Osborne CK,et a1.Malignant Tumom of theBreast.In:Devita VTJr.Cancer:Principles and Practice of Oncology(6th Edition)[M].Lipincott Williams&Wilkins,2001.651—652.
[2] Mack M G,Straub R,Eichler K. et a1.Breast cancer metastases in liver: laser—induced interstitial thermotherapylocal tumor control rate and survival data [J]. Radiology, 2004。233(2):400-409.
[3] AbelofMD,Lichter AS,Niederhuber JE,et a1.Breast.In:AbolofMD,et a1.Clinical Oncology(2nd Edition)[M].Churchill Ijvinstone ,1999.251—254.
[4] Mayor S,Chemotherapy and hormonal treatments improve the 15 year survival rate for breast cancer. [J] 2005,330:1167.
[5] Martin TJ,Moseley JM.Mechanisms in the skeletal complications of breast cancer[J].Endecr Relat Cancer,2000,7:271—284.
[6] Insa A,Llueh A,Prosper F,et a1.Prognostic factors predictingsurvival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients.[J] Breast Cancer Res Treat,1999,56:67—78.
[7] Crivellari D,Pagani 0,Vewn~i A,et a1.Intematiorml breast cttncer study group.Hig}l incidence of central ne~,ous system invoh,ement in patients with metastatic OF locally advanced breast cancer treated withepirubicin and docetaxel [J].Ann Oncol,2001;12:353—356
[8] Abali H.Celik I.High incidence of central nervous system involvement in patients with breast cancer treated with epirubicin and decetaxel[J]. Am J Clin Oncol。20o2;25:632—633
[9] Lee YT. Breast carcinoma: pattem of metastases at autopsy [J].J Surg Oncol,1983,23(3):175—180.[4] S vetlovska D. Mardiak J. Treatment strategy of early—stage breast cancer[J].Bratisl Lek Listy,2005,106(11):362-365]
[10]顾兴华,夏康适.骨转移癌药物治疗近况.[J]国外医学肿瘤.5~ ,1994,21(4);234
[11]徐兵河.乳腺癌[M].北京:北京大学医学出版社,2005.5
[12]徐兵河.来曲唑治疗绝经后妇女晚期乳腺癌临床研究[J].中国新药杂志,2001,10(1O):763—766。
[13] Selzner M , Morse MA , Vredenburgh JJ , et al . Liver metastases from breast cancer : longterm survival after curative resection[J ] . Surgery , 2000 , 127 (4) :383 - 389.
[14] Solomayer EF,Dicl I,Meyberg GC,eI al.Metastatic breast cancer:clinical course,prognosis and therapy related to the first site of metastasis[J].Breast Cancer Ras Treat,2000,59:271—278
[15] Chthie T,Chung,Robert W ,et a1.Goals and Objectives in the Management of Metastatic Breast Cancer[J].The Oncdo6st,2003,8: 514—520
[16] Raab R.Nussbaum KT,Behrend M .et a1.I.iver metastases of breast cancer:results of liver resection.[J] Anticancer Res,1998。18(3C):223l～2233
[17] Coleman RE,Smith P,RubensRD.Clinical cours and prognostic factors following bone recurrence from breast cancer[J].Br J Cancer。1998.77:336—340.
[18] Demicheli R , Bonadonna G, Hrushesky WJ , et al . Menopausal status dependence of t he timing of breast cancer recurrence after surgical removal of t he primary tumour [J ] . Breast Cancer Res , 2004 , 6 (6) :R689 - R696.
[19] Uzzan B , Nicolas P , Cucherat M , et al . Microvessel density as a prognostic factor in women with breast cancer : a systematic review of t he literature and meta-analysis [J] . Cancer Res , 2004 , 64 (9) :2 941 - 2 955.
[20] Hilsenbeck SG, Ravdin PM , de Moor CA , et al . Time-dependence of hazard ratios for prognostic factors in primary breast cancer [J]. Breast Cancer Res Treat , 1998 , 52 (1 -3) :227 - 237.
[21] Brown JM , Giaccia AJ . The unique physiology of solid tumors : opportunities (and problems) for cancer therapy[J ] . Cancer Res , 1998 , 58 (7) :1 408 - 1 416.
[22] van der Wal BC , Butzelaar RM , van der Meij S , et al . Axillary lymph node ratio and total number of removed lymph nodes : predictors of survival in stage I and II breast cancer [J ] . Eur J S urg Oncol , 2002 , 28 (5) :481 - 489.
[23] Ferretti G,Felici A,Papaldo P,et a1.HER2/neu role in breast cancer:from a prognostic foe to apredictive friend[J].Curr Opin Obstet Gynecol,2007,19:56-62.
[24] Quenel N , Wafflart J , Bergonie F . The prognostic value of cerbB-2 in primary breast carcinoma : A study on 942 cases [J] . Breast Cancer Res Treatment,1995,3(3):283～285.
[25] Petit T, Borel C, Ghnassia J P,Rodier J F,etal.Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. [J] Clin Cancer Res. 2001,7(6): 1577～1581
[26] Slamon D J,Leyland Jones B, Shak S,etal. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N Engl [J] Med. 2001,344(11): 783～792
[27]
[28] Kaptain S , Tan L K, Chen B. Her-2/ neu and breast cancer [J] . Diagn Mol Pathol , 2001 , 10 (3) :139 - 152.
[29] Konecny G, Pauletti G, Pegram M , et al . Quantitative association between HER-2/ neu and steroid hormone receptors in hormone receptor-positive primary breast cancer [J] . J N at Cancer I nst , 2003 , 95 (2) :142 - 153.
[30] Emi Y, Kitamura K, Shikada Y, et al . Metastatic breast cancer with HER-2/ neu-positive cells tends to have a morbid prognosis [J]. Surgery , 2002 , 131 (1 Suppl) :S217 - S221.
[31] Lin NU , Winer EP. Brain metastases : the HER-2 paradigm [J] . Clin Cancer Res , 2007 , 13 (6) :1 648 - 1 655.
[32] Van Tienhoven G, Voogd AC , Peterse JL , et al . Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials ( EORTC 10801 and DBCG-82 TM) . EORTC Breast Cancer Cooperative Group and the Danish Breast Cancer Cooperative Group [J]. Eur J Cancer , 1999 , 35 (1) :32 - 38.
[33] Bedwinek J .Natural history and management of isolated local-regional recurrence following mastectomy [J] . Semin Radiat Oncol , 1994 , 4 (4) :260 - 269.
[34] Willner J , Kiricuta IC , Kolbl O. Locoregional recurrence of breast cancer following mastectomy : always a fatal event ? Results of univariate and multivariate analysis [J]. I nt J Ra-diat Oncol B iol Phys , 1997 , 37 (4) :853 - 863.
[1]徐兵河,主编.乳腺癌(乳腺癌的分子靶向治疗)[M].第1版.北京大学医学出版社,2005,9:225.
[2] Emen LA . Trastuzumab: targeted therapy for the management of Her -2 overexpressing metastatic breast cancer[ J ]. Am J Ther, 2005, 72 (3) : 243～253.
[3] Burstein HJ , W iner EP. HER 2 or not HER 2: that is the question. [ J ]. Clin Oncol, 2005, 23 (16): 3656-3659
[4] Slamon D J,Leyland Jones B, Shak S,etal. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N Engl [J] Med. 2001,344(11): 783-792.
[5] Cobleigh MA, Vogel CL , Tripathy D , et al. Multinational study of the efficacy and safety of humanized anti-HER-2 monoclonal antibody in women who have HER-2 ovexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. [J]Clin Oncol, 1999, 17 (9)∶2639 -2648.
[6] Burstein HJ, Kuter I, Campos SM. Clinical activity of trastuzumab and vinorelbine in women with HER-overexpressing metastatic breast cancer[ J ]. J Clin Oncol, 2001, 19(10)∶2722 -2730.
[7] Yang SP, Song ST , Song HF, et al. Effect of a new antisense oligodeoxyribonucleotide, HA 824, targeting at her-2mRNA on HER-2 expression chin . [J]Pharmacol toxicol,2003,17(2):87-92
[8] Coussens L, YangFeng TL, L iao YC, et al Tyrosine kinase receptor with extensive homology to EGC receptor shares chromosomal location with neu oncogene. [J]Science , 1985, 230 1132 -1139.
[9]孙燕、李丽庆、宋三泰等,注射用赫赛汀治疗晚期乳腺癌临床验证报告。[J]中华肿瘤杂志,2003:581-583.
[10] Mayor S,Chemotherapy and hormonal treatments improve the 15 year survival rate for breast cancer. [J] 2005,330:1167.
[11] Jeonsuu H et al,Adjuvant decetaxel or vinorelbine with or without trastuzumab for breast cancer.N Engl [J] Med 2006;354:821-31.
[12] Fuchs IB,LantS,Bueh H, et al.Analysis of Her-2 and Her-4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin)[J]. Breast cancer Restrect,2003,82(1):23-28.
[13] Chow LWC,Loo WTY.The differential effects of clophosphamide,epirubicinand fluorouracil on apoptotic marker(CPP 32) , proapoptotic protein ( p21waf 1) and anti apoptotic protein ( bcl-2) in breast cancer cells. [J] Breast Cancer Res Treat,2003,80(3):239-244.
[14] Robbins GF,Berg G.Curablity of Patients with invasive-breast carcinoma based on a 30year study.World [J]Surg,1997,1:284-286.
[15] Bonnadonna G,Valagussa P,Brambilla C,et al.Priamry chemotherapy in operable breast cancer:Eight-year experience at the Milan Cancer Institute. [J] Clin Oncol,1998,16:93-100..
[16] Van der Geer P, Hunter T, L indberg RA.Receptor protein–tyro-sine kinases and their single transduction pathways [ J ]. Ann Rev Cell B iol, 1994, 10: 251～337.
[17] Edmundson GK, Vicini FA, Chen PY, et al.Dosimetric characteristicsof the Mammo Site RTS, a new breast brachytherapy applicator. Int [J] Radiat Oncol Biol Phys, 2002,52: 1132.
[18] Lu C,Spees C,Zhang Y, et al.Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors[J] .Jnatl Cancer Inst,2003,95(24):1825-1833.
[19] Buchholz TA, Strom EA, M cNeese MD, et al. Radiation therapy as an adjuvant treatment after sentinel lymph node surgery for breast cancer. [J] Surg Clin North Am, 2003,83(4): 911.
[20] Aebi S,Gelber S,Castiglione-Gertsch M, et al.Is chemotherapy alone adequate for young women with oestrongen-receptor-positive breast cancer[J].Lancet,2000,355:1869-1874
[21] Early Breast Cancer Trialists,Collaborative Group.Tamoxifen for early breast cancer :an overview of randomised trails. [J]Lancet 1998,351:1451-1467
[22] Goldhirsch A,Click JH ,Celber RD,et al.Meeting highlights:International consensns panel on the treatment of primary breast cancer [J] NCI 1998,90:1601-1608.
[23] Wood ER,Truesdale AT,McDonald OB, et al.A unique structure for epidemical growth factor bound to GW-572016(lapatinib):relationships among protein conformation ,inhibitor off-rate,and receptor activity in tumor cells[J].Cancer Res,2004,64:6652-6659.
[24] Spector NL,Xia W,Burris H, et al.A study of the biological effects lapatinib(GW-572016),a reversible inhibitor of ErbB-1 and ErbB-2 tyrosine kinases,on tumor growth and survival pathways in patients with advanced malignancies[J]. ClinOncol,2005,23:lapatinib2502-2512.
[25] Blackwell KL,Kaplan EH,Franco SX, et al.A phase II,open-label,multicenter study of GW-572016 in patients with trastuzumab - refractory metastatic breast cancer[J].Proe Am Sco Clin Oncol,2004,23:196(abstr3006).
[26] Burstein H,Stomiomno AM,Franco S, et al.A phase II,open-label,multicenter study of lapatinib in two cohorts of patients with advanced or metastatic breast cancer who have progressed while receiving trastuzumab-containing regiments[J].Ann Oncol,2004,15:(abstr1040,suppl 3).
[27] Konecny G, Pauletti G, Pegram M , et al . Quantitative association between HER-2/ neu and steroid hormone receptors in hormone receptor-positive primary breast cancer [J] . J N at Cancer I nst , 2003 , 95 (2) :142 - 153.
[28] Subbaramiaiah K,Norton L,Geral W, et al.Cyclooxygenase-2 is overexpressed in Her-2/neu-positive breast cancer:evidence for involvement of AP-1 and PGA3. a) [J].Biol Chem,2002,277(21):18649-57.
[29] Kaptain S , Tan L K, Chen B. Her-2/ neu and breast cancer [J] . Diagn Mol Pathol , 2001 , 10 (3) :139 - 152.
[30] Subbaramiaiah K,hart JC,Norton L, et al.Microtubule-interfering agent stimulate the transcription of cycloo xygenase-2.Evidence for involvement of ERK1/2 and p38 mitogen-activated protein kinase pathways[J]. Biol Chem,2000,275(20):14838-14845.
[31] Von Minckwitz G,Blohmer JU,Raab G,et al.In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer :[J]The GEPARTRIO pilot study.Ann Oncol, 2005,16:56-63.
[32] Wolmark N,Wang J,Mamounas E,et al.Preoperative chemotherapy in patients with operable breast cancer:Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. [J] Natl Cancer Inst Monogr ,2001,30:96-102 .
[33] Yancapoulos GD,Davis S,Gale NW, et al.Vascular specific factors and blood vessel formation[J].Nature,2000,407:242-248.
[34] Hlupic L , Jakic - Razumovic J , Bozikov J ,etal.Prognostic value of different factors in breast carcinoma. [J] Tumor ,2004,90(1):112-119 .
[35] Chen AM,Meric-Bernstam F,Hunt KK, et al.Breast conservation after neoadjuvant chemotherapy : The MD Anderson cancer center experience. [J]Clin Oncol 2004,22:2303-2312.
[36] Bear HD,Anderson S,Smith RE,et al.A randomized trial comparing preoperative(preop) doxorubicin/cyclophosphamide(AC) to preop AC followed by preop docetaxel (T) and to preop AC followed by postoperative (postop) T in patients (pts) with operable carcinoma of the breast:Results of NSABP B-27. [J]Breast Cancer Res Treat ,2004,88:16.
[37] Chan S,Johnston SR,Scheulen ME, et al.Phase II safety and activity trial of two dose levels of CCI-779 in women with previously treated locally advanced or metastatic cancer -Interim analysis. [J] Breast cancer Res Treat,2002(suppl 10),76:S132(abstr).
[38] Mayor S.Chemotherapy and hormonal treatments improve the 15 year survival rate for breast cancer. [J], 2005,330:1167.
[39] Blackwell KL,Kaplan EH,Franco SX, et al.A phase II,open-label,multicenter study of GW-572016 in patients with trastuzumab-refractory metastatic breast cancer. [J]Proe Am Sco Clin Oncol,2004,23:196.
[40] Lu C,Spees C,Zhang Y, et al.Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. [J]natl Cancer Inst,2003,95(24):1825-1833.
[41] Tayama T, FujiiU, Toh G, et al. The synergistic clinical effectof auologous tumor2stimulated T lymphocyte and herceptin on the immunotherapyof breast cancer. [J] Yamana ASCO Meeting Abstracts, 2005,23:775.
[42] Van der Geer P, Hunter T, L indberg RA.Receptor protein–tyro-sine kinases and their single transduction pathways. [J] Ann Rev Cell B iol, 1994, 10: 251～337.
[43] Jeonsuu H,Adjuvant decetaxel or vinorelbine with or without trastuzumab for breast cancer.N Engl [J] Med ,2006,354:821-831.
[44] Cobleigh MA, Vogel CL , Tripathy D , et al. Multinational study of the efficacy and safety of humanized anti-HER-2 monoclonal antibody in women who have HER-2 ovexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. [J] Clin Oncol, 1999, 17 (9)∶2639 -2648.
[45] Fuchs IB,Lant S,Bueh H, et al.Analysis of Her-2 and Her-4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin). [J]Breast cancer Res Treat,2003,82(1):23-28.
[46] Coussens L, YangFeng TL, L iao YC, et al Tyrosine kinase receptor with extensive homology to EGC receptor shares chromosomal location with neu oncogene. [J]Science , 1985, 230 1132 -1139.
[2] Mack M G,Straub R,Eichler K. et a1.Breast cancer metastases in liver: laser—induced interstitial thermotherapylocal tumor control rate and survival data [J]. Radiology, 2004。233(2):400-409.
[3] AbelofMD,Lichter AS,Niederhuber JE,et a1.Breast.In:AbolofMD,et a1.Clinical Oncology(2nd Edition)[M].Churchill Ijvinstone ,1999.251—254.
[4] Mayor S,Chemotherapy and hormonal treatments improve the 15 year survival rate for breast cancer. [J] 2005,330:1167.
[5] Martin TJ,Moseley JM.Mechanisms in the skeletal complications of breast cancer[J].Endecr Relat Cancer,2000,7:271—284.
[6] Insa A,Llueh A,Prosper F,et a1.Prognostic factors predictingsurvival from first recurrence in patients with metastatic breast cancer: analysis of 439 patients.[J] Breast Cancer Res Treat,1999,56:67—78.
[7] Crivellari D,Pagani 0,Vewn~i A,et a1.Intematiorml breast cttncer study group.Hig}l incidence of central ne~,ous system invoh,ement in patients with metastatic OF locally advanced breast cancer treated withepirubicin and docetaxel [J].Ann Oncol,2001;12:353—356
[8] Abali H.Celik I.High incidence of central nervous system involvement in patients with breast cancer treated with epirubicin and decetaxel[J]. Am J Clin Oncol。20o2;25:632—633
[9] Lee YT. Breast carcinoma: pattem of metastases at autopsy [J].J Surg Oncol,1983,23(3):175—180.[4] S vetlovska D. Mardiak J. Treatment strategy of early—stage breast cancer[J].Bratisl Lek Listy,2005,106(11):362-365]
[10]顾兴华,夏康适.骨转移癌药物治疗近况.[J]国外医学肿瘤.5~ ,1994,21(4);234
[11]徐兵河.乳腺癌[M].北京:北京大学医学出版社,2005.5
[12]徐兵河.来曲唑治疗绝经后妇女晚期乳腺癌临床研究[J].中国新药杂志,2001,10(1O):763—766。
[13] Selzner M , Morse MA , Vredenburgh JJ , et al . Liver metastases from breast cancer : longterm survival after curative resection[J ] . Surgery , 2000 , 127 (4) :383 - 389.
[14] Solomayer EF,Dicl I,Meyberg GC,eI al.Metastatic breast cancer:clinical course,prognosis and therapy related to the first site of metastasis[J].Breast Cancer Ras Treat,2000,59:271—278
[15] Chthie T,Chung,Robert W ,et a1.Goals and Objectives in the Management of Metastatic Breast Cancer[J].The Oncdo6st,2003,8: 514—520
[16] Raab R.Nussbaum KT,Behrend M .et a1.I.iver metastases of breast cancer:results of liver resection.[J] Anticancer Res,1998。18(3C):223l～2233
[17] Coleman RE,Smith P,RubensRD.Clinical cours and prognostic factors following bone recurrence from breast cancer[J].Br J Cancer。1998.77:336—340.
[18] Demicheli R , Bonadonna G, Hrushesky WJ , et al . Menopausal status dependence of t he timing of breast cancer recurrence after surgical removal of t he primary tumour [J ] . Breast Cancer Res , 2004 , 6 (6) :R689 - R696.
[19] Uzzan B , Nicolas P , Cucherat M , et al . Microvessel density as a prognostic factor in women with breast cancer : a systematic review of t he literature and meta-analysis [J] . Cancer Res , 2004 , 64 (9) :2 941 - 2 955.
[20] Hilsenbeck SG, Ravdin PM , de Moor CA , et al . Time-dependence of hazard ratios for prognostic factors in primary breast cancer [J]. Breast Cancer Res Treat , 1998 , 52 (1 -3) :227 - 237.
[21] Brown JM , Giaccia AJ . The unique physiology of solid tumors : opportunities (and problems) for cancer therapy[J ] . Cancer Res , 1998 , 58 (7) :1 408 - 1 416.
[22] van der Wal BC , Butzelaar RM , van der Meij S , et al . Axillary lymph node ratio and total number of removed lymph nodes : predictors of survival in stage I and II breast cancer [J ] . Eur J S urg Oncol , 2002 , 28 (5) :481 - 489.
[23] Ferretti G,Felici A,Papaldo P,et a1.HER2/neu role in breast cancer:from a prognostic foe to apredictive friend[J].Curr Opin Obstet Gynecol,2007,19:56-62.
[24] Quenel N , Wafflart J , Bergonie F . The prognostic value of cerbB-2 in primary breast carcinoma : A study on 942 cases [J] . Breast Cancer Res Treatment,1995,3(3):283～285.
[25] Petit T, Borel C, Ghnassia J P,Rodier J F,etal.Chemotherapy response of breast cancer depends on HER-2 status and anthracycline dose intensity in the neoadjuvant setting. [J] Clin Cancer Res. 2001,7(6): 1577～1581
[26] Slamon D J,Leyland Jones B, Shak S,etal. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N Engl [J] Med. 2001,344(11): 783～792
[27]
[28] Kaptain S , Tan L K, Chen B. Her-2/ neu and breast cancer [J] . Diagn Mol Pathol , 2001 , 10 (3) :139 - 152.
[29] Konecny G, Pauletti G, Pegram M , et al . Quantitative association between HER-2/ neu and steroid hormone receptors in hormone receptor-positive primary breast cancer [J] . J N at Cancer I nst , 2003 , 95 (2) :142 - 153.
[30] Emi Y, Kitamura K, Shikada Y, et al . Metastatic breast cancer with HER-2/ neu-positive cells tends to have a morbid prognosis [J]. Surgery , 2002 , 131 (1 Suppl) :S217 - S221.
[31] Lin NU , Winer EP. Brain metastases : the HER-2 paradigm [J] . Clin Cancer Res , 2007 , 13 (6) :1 648 - 1 655.
[32] Van Tienhoven G, Voogd AC , Peterse JL , et al . Prognosis after treatment for loco-regional recurrence after mastectomy or breast conserving therapy in two randomised trials ( EORTC 10801 and DBCG-82 TM) . EORTC Breast Cancer Cooperative Group and the Danish Breast Cancer Cooperative Group [J]. Eur J Cancer , 1999 , 35 (1) :32 - 38.
[33] Bedwinek J .Natural history and management of isolated local-regional recurrence following mastectomy [J] . Semin Radiat Oncol , 1994 , 4 (4) :260 - 269.
[34] Willner J , Kiricuta IC , Kolbl O. Locoregional recurrence of breast cancer following mastectomy : always a fatal event ? Results of univariate and multivariate analysis [J]. I nt J Ra-diat Oncol B iol Phys , 1997 , 37 (4) :853 - 863.
[1]徐兵河,主编.乳腺癌(乳腺癌的分子靶向治疗)[M].第1版.北京大学医学出版社,2005,9:225.
[2] Emen LA . Trastuzumab: targeted therapy for the management of Her -2 overexpressing metastatic breast cancer[ J ]. Am J Ther, 2005, 72 (3) : 243～253.
[3] Burstein HJ , W iner EP. HER 2 or not HER 2: that is the question. [ J ]. Clin Oncol, 2005, 23 (16): 3656-3659
[4] Slamon D J,Leyland Jones B, Shak S,etal. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.N Engl [J] Med. 2001,344(11): 783-792.
[5] Cobleigh MA, Vogel CL , Tripathy D , et al. Multinational study of the efficacy and safety of humanized anti-HER-2 monoclonal antibody in women who have HER-2 ovexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. [J]Clin Oncol, 1999, 17 (9)∶2639 -2648.
[6] Burstein HJ, Kuter I, Campos SM. Clinical activity of trastuzumab and vinorelbine in women with HER-overexpressing metastatic breast cancer[ J ]. J Clin Oncol, 2001, 19(10)∶2722 -2730.
[7] Yang SP, Song ST , Song HF, et al. Effect of a new antisense oligodeoxyribonucleotide, HA 824, targeting at her-2mRNA on HER-2 expression chin . [J]Pharmacol toxicol,2003,17(2):87-92
[8] Coussens L, YangFeng TL, L iao YC, et al Tyrosine kinase receptor with extensive homology to EGC receptor shares chromosomal location with neu oncogene. [J]Science , 1985, 230 1132 -1139.
[9]孙燕、李丽庆、宋三泰等,注射用赫赛汀治疗晚期乳腺癌临床验证报告。[J]中华肿瘤杂志,2003:581-583.
[10] Mayor S,Chemotherapy and hormonal treatments improve the 15 year survival rate for breast cancer. [J] 2005,330:1167.
[11] Jeonsuu H et al,Adjuvant decetaxel or vinorelbine with or without trastuzumab for breast cancer.N Engl [J] Med 2006;354:821-31.
[12] Fuchs IB,LantS,Bueh H, et al.Analysis of Her-2 and Her-4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin)[J]. Breast cancer Restrect,2003,82(1):23-28.
[13] Chow LWC,Loo WTY.The differential effects of clophosphamide,epirubicinand fluorouracil on apoptotic marker(CPP 32) , proapoptotic protein ( p21waf 1) and anti apoptotic protein ( bcl-2) in breast cancer cells. [J] Breast Cancer Res Treat,2003,80(3):239-244.
[14] Robbins GF,Berg G.Curablity of Patients with invasive-breast carcinoma based on a 30year study.World [J]Surg,1997,1:284-286.
[15] Bonnadonna G,Valagussa P,Brambilla C,et al.Priamry chemotherapy in operable breast cancer:Eight-year experience at the Milan Cancer Institute. [J] Clin Oncol,1998,16:93-100..
[16] Van der Geer P, Hunter T, L indberg RA.Receptor protein–tyro-sine kinases and their single transduction pathways [ J ]. Ann Rev Cell B iol, 1994, 10: 251～337.
[17] Edmundson GK, Vicini FA, Chen PY, et al.Dosimetric characteristicsof the Mammo Site RTS, a new breast brachytherapy applicator. Int [J] Radiat Oncol Biol Phys, 2002,52: 1132.
[18] Lu C,Spees C,Zhang Y, et al.Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors[J] .Jnatl Cancer Inst,2003,95(24):1825-1833.
[19] Buchholz TA, Strom EA, M cNeese MD, et al. Radiation therapy as an adjuvant treatment after sentinel lymph node surgery for breast cancer. [J] Surg Clin North Am, 2003,83(4): 911.
[20] Aebi S,Gelber S,Castiglione-Gertsch M, et al.Is chemotherapy alone adequate for young women with oestrongen-receptor-positive breast cancer[J].Lancet,2000,355:1869-1874
[21] Early Breast Cancer Trialists,Collaborative Group.Tamoxifen for early breast cancer :an overview of randomised trails. [J]Lancet 1998,351:1451-1467
[22] Goldhirsch A,Click JH ,Celber RD,et al.Meeting highlights:International consensns panel on the treatment of primary breast cancer [J] NCI 1998,90:1601-1608.
[23] Wood ER,Truesdale AT,McDonald OB, et al.A unique structure for epidemical growth factor bound to GW-572016(lapatinib):relationships among protein conformation ,inhibitor off-rate,and receptor activity in tumor cells[J].Cancer Res,2004,64:6652-6659.
[24] Spector NL,Xia W,Burris H, et al.A study of the biological effects lapatinib(GW-572016),a reversible inhibitor of ErbB-1 and ErbB-2 tyrosine kinases,on tumor growth and survival pathways in patients with advanced malignancies[J]. ClinOncol,2005,23:lapatinib2502-2512.
[25] Blackwell KL,Kaplan EH,Franco SX, et al.A phase II,open-label,multicenter study of GW-572016 in patients with trastuzumab - refractory metastatic breast cancer[J].Proe Am Sco Clin Oncol,2004,23:196(abstr3006).
[26] Burstein H,Stomiomno AM,Franco S, et al.A phase II,open-label,multicenter study of lapatinib in two cohorts of patients with advanced or metastatic breast cancer who have progressed while receiving trastuzumab-containing regiments[J].Ann Oncol,2004,15:(abstr1040,suppl 3).
[27] Konecny G, Pauletti G, Pegram M , et al . Quantitative association between HER-2/ neu and steroid hormone receptors in hormone receptor-positive primary breast cancer [J] . J N at Cancer I nst , 2003 , 95 (2) :142 - 153.
[28] Subbaramiaiah K,Norton L,Geral W, et al.Cyclooxygenase-2 is overexpressed in Her-2/neu-positive breast cancer:evidence for involvement of AP-1 and PGA3. a) [J].Biol Chem,2002,277(21):18649-57.
[29] Kaptain S , Tan L K, Chen B. Her-2/ neu and breast cancer [J] . Diagn Mol Pathol , 2001 , 10 (3) :139 - 152.
[30] Subbaramiaiah K,hart JC,Norton L, et al.Microtubule-interfering agent stimulate the transcription of cycloo xygenase-2.Evidence for involvement of ERK1/2 and p38 mitogen-activated protein kinase pathways[J]. Biol Chem,2000,275(20):14838-14845.
[31] Von Minckwitz G,Blohmer JU,Raab G,et al.In vivo chemosensitivity-adapted preoperative chemotherapy in patients with early-stage breast cancer :[J]The GEPARTRIO pilot study.Ann Oncol, 2005,16:56-63.
[32] Wolmark N,Wang J,Mamounas E,et al.Preoperative chemotherapy in patients with operable breast cancer:Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. [J] Natl Cancer Inst Monogr ,2001,30:96-102 .
[33] Yancapoulos GD,Davis S,Gale NW, et al.Vascular specific factors and blood vessel formation[J].Nature,2000,407:242-248.
[34] Hlupic L , Jakic - Razumovic J , Bozikov J ,etal.Prognostic value of different factors in breast carcinoma. [J] Tumor ,2004,90(1):112-119 .
[35] Chen AM,Meric-Bernstam F,Hunt KK, et al.Breast conservation after neoadjuvant chemotherapy : The MD Anderson cancer center experience. [J]Clin Oncol 2004,22:2303-2312.
[36] Bear HD,Anderson S,Smith RE,et al.A randomized trial comparing preoperative(preop) doxorubicin/cyclophosphamide(AC) to preop AC followed by preop docetaxel (T) and to preop AC followed by postoperative (postop) T in patients (pts) with operable carcinoma of the breast:Results of NSABP B-27. [J]Breast Cancer Res Treat ,2004,88:16.
[37] Chan S,Johnston SR,Scheulen ME, et al.Phase II safety and activity trial of two dose levels of CCI-779 in women with previously treated locally advanced or metastatic cancer -Interim analysis. [J] Breast cancer Res Treat,2002(suppl 10),76:S132(abstr).
[38] Mayor S.Chemotherapy and hormonal treatments improve the 15 year survival rate for breast cancer. [J], 2005,330:1167.
[39] Blackwell KL,Kaplan EH,Franco SX, et al.A phase II,open-label,multicenter study of GW-572016 in patients with trastuzumab-refractory metastatic breast cancer. [J]Proe Am Sco Clin Oncol,2004,23:196.
[40] Lu C,Spees C,Zhang Y, et al.Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors. [J]natl Cancer Inst,2003,95(24):1825-1833.
[41] Tayama T, FujiiU, Toh G, et al. The synergistic clinical effectof auologous tumor2stimulated T lymphocyte and herceptin on the immunotherapyof breast cancer. [J] Yamana ASCO Meeting Abstracts, 2005,23:775.
[42] Van der Geer P, Hunter T, L indberg RA.Receptor protein–tyro-sine kinases and their single transduction pathways. [J] Ann Rev Cell B iol, 1994, 10: 251～337.
[43] Jeonsuu H,Adjuvant decetaxel or vinorelbine with or without trastuzumab for breast cancer.N Engl [J] Med ,2006,354:821-831.
[44] Cobleigh MA, Vogel CL , Tripathy D , et al. Multinational study of the efficacy and safety of humanized anti-HER-2 monoclonal antibody in women who have HER-2 ovexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. [J] Clin Oncol, 1999, 17 (9)∶2639 -2648.
[45] Fuchs IB,Lant S,Bueh H, et al.Analysis of Her-2 and Her-4 in human myocardium to clarify the cardiotoxicity of trastuzumab (Herceptin). [J]Breast cancer Res Treat,2003,82(1):23-28.
[46] Coussens L, YangFeng TL, L iao YC, et al Tyrosine kinase receptor with extensive homology to EGC receptor shares chromosomal location with neu oncogene. [J]Science , 1985, 230 1132 -1139.